Abstracts tagged "longitudinal studies"

Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 709 • 2015 ACR/ARHP Annual Meeting
Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Runsheng Wang¹, Sherine Gabriel² and Michael M. Ward¹, ¹NIH/NIAMS, Bethesda, MD, ²Division of Rheumatology; Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The long-term outcome of patients with non-radiographic axial spondyloarthritis (nr-axSpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective…
Abstract Number: 712 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Anti-TNF Treatment in a Longitudinally Followed Ankylosing Spondylitis (AS) Cohort
Mary Gibson¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Colton Pence¹, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…
Abstract Number: 716 • 2015 ACR/ARHP Annual Meeting
Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Amita Aggarwal¹, Sudhir sinha², Ranjan Gupta³, Liza Rajasekhar⁴, Akhilesh Yadav³, Ramnath Misra¹ and Virsingh Negi⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ³Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers have a potential for identification, follow-up and assessment of response to treatment in patients with lupus nephritis. Urinary proteomics can help in…
Abstract Number: 849 • 2015 ACR/ARHP Annual Meeting
A Computational Tool for Individualized Prognosis of Percent of Predicted Forced Vital Capacity Trajectories in Systemic Sclerosis
Peter Schulam¹, Colin Ligon², Robert Wise³, Laura K. Hummers⁴, Fredrick M. Wigley⁵ and Suchi Saria^1,6, ¹Department of Computer Science, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Departments of Biostatistics, and Health Policy and Management, Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Interstitial lung disease (ILD) is a common cause of mortality in systemic sclerosis (Ssc). Decreased forced vital capacity (FVC) in Ssc-ILD is associated with…
Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Ketti Terry⁴, Kenneth Kwok⁵, Irina Lazariciu⁶, Chudy Nduaka⁷, Carol A. Connell⁴, Ryan DeMasi⁵ and Lisy Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Quintiles, Saint-Laurent, QC, Canada, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
Abstract Number: 1708 • 2015 ACR/ARHP Annual Meeting
Predictors of Depression Severity in Ankylosing Spondylitis
Mark Hwang¹, MinJae Lee², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Shervin Assassi⁶, Laura A. Diekman⁷, Mohammad H. Rahbar⁸, Michael H. Weisman⁹ and John D. Reveille¹⁰, ¹Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁷Rheumatology, University of Texas Medical School, Houston, TX, ⁸The University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Depression is a known comorbidity of ankylosing spondylitis (AS) with over one-third of AS patients affected and increased depression-rate ratio compared to the general…
Abstract Number: 2071 • 2015 ACR/ARHP Annual Meeting
Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Ranjan Gupta¹, Amita Aggarwal², Sudhir sinha³, Liza Rajasekhar⁴, Akhilesh Yadav¹, Priyanka Gaur¹, Ramnath Misra² and Virsingh Negi⁵, ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers may help in identification, treatment and assessment of response to therapy in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by…
Abstract Number: 2693 • 2015 ACR/ARHP Annual Meeting
Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis
Maria LE Andersson¹, Kristina Forslind² and Ingiäld Hafström³, ¹R&D Centre Spenshult,Halmstad, Halmstad, Sweden, ²Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ³Rheumatology Dept, Karoliska Institute, Stockholm, Sweden
Background/Purpose: To compare patient and disease characteristics over the first 8 years of disease in a large inception cohort of early RA patients included 1992…
Abstract Number: 3068 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹⁴ and Peter A. Merkel⁸, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of California Los Angeles, Santa Monica, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹²Division of Rheumatology, Johns Hopkins, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: This study aimed to describe disease-related damage in Takayasu's arteritis (TAK) and evaluate damage assessment tools using data from a large longitudinal cohort. …
Abstract Number: 3146 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Adults with JIA – a 30 Year Longitudinal Study
Anita Tollisen^1,2,3, Anne Marit Selvaag¹, Hanne A. Aulie¹, Anners Lerdal^4,5 and Berit Flato^1,2, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ²Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³Department of Medicine, Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway, ⁴Faculty of Medicine, Institute of Health and Society, University of Oslo, Oslo, Norway, ⁵Lovisenberg Diakonale Hospital, Oslo, Oslo, Norway
Background/Purpose: Improvement of health-related quality of life (HRQOL) is a central aim in treatment of patients with JIA. The primary aim of the study is…
Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years
J. Wollenhaupt¹, J. Silverfield², E.B. Lee³, S.P. Wood⁴, K. Terry⁴, H. Nakamura⁵, K. Kwok⁶, A. Anisfeld⁶, C. Nduaka⁴, R. Riese⁴ and L. Wang⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Tokyo, Japan, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 2654 • 2014 ACR/ARHP Annual Meeting
Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study
Yang Gao¹, Yi Lo¹, Jacky Wan², Esther YY Lau² and Mo Yin Mok¹, ¹Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ²Department of Psychology, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Cognitive impairment is commonly reported in patients with systemic lupus erythematosus (SLE) and its associations with neuropsychiatric involvement (NPSLE) and psychiatric factors have been…
Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Michael Morgan¹, Andreas Reimold², Ted R. Mikuls³, Gail Kerr⁴ and Grant W. Cannon⁵, ¹Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Washington DC VA and Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].